Bristol-Myers Squibb has completed the acquisition of Amira Pharmaceuticals, with the privately held company becoming a wholly owned subsidiary.
The acquisition includes Amira’s fibrosis programme and lead asset AM152, a lysophosphatidic acid 1 receptor antagonist set to start Phase IIa proof-of-confidence studies to treat idiopathic pulmonary fibrosis and scleroderma.
Go deeper with GlobalData
The acquisition marks Bristol-Myers Squibb’s entrance into fibrotic diseases, which the company has highlighted as an area of unmet medical need.
The transaction, originally announced in July, has now passed all customary regulatory approval obligations.
